Dosing & Uses
Dosage Forms & Strengths
amitriptyline/perphenazine
tablet
- 10mg/2mg
- 25mg/2mg
- 10mg/4mg
- 25mg/4mg
- 50mg/4mg
Anxiety or Agitation with Depression
Indicated for (1) moderate-to-severe anxiety and/or agitation and depressed mood, (2) depression in whom anxiety and/or agitation are severe, and (3) depression and anxiety associated with chronic physical disease
Initial: 25 mg/2 mg or 25 mg/4 mg PO TID/QID, OR 50 mg/4 mg PO BID
Maintenance: 2 mg/25 mg or 4 mg/25 mg PO BID/QID, OR 50 mg/4 mg PO BID
10 mg/ 2 mg and 10 mg/4 mg can be used to increase flexibility in adjusting maintenance dosage to the lowest amount consistent with relief of symptoms
Do not exceed daily dose of 200 mg/16 mg
Schizophrenia with Depression
Indicated for patients with schizophrenic who have associated depressive symptoms
Initial: 50 mg/8 mg (ie, 2 tablets of 25 mg/4 mg) PO BID/TID; if needed a fourth dose may be given at bedtime
Maintenance: 2 mg/25 mg or 4 mg/25 mg PO BID/QID, OR 50 mg/4 mg PO BID
10 mg/ 2 mg and 10 mg/4 mg can be used to increase flexibility in adjusting maintenance dosage to the lowest amount consistent with relief of symptoms
Do not exceed daily dose of 200 mg/16 mg
Dosing Considerations
Depending on the condition being treated, therapeutic response may not be observed for several days up to 2-3 weeks, or longer
After a satisfactory response is noted, dosage should be reduced to the smallest amount necessary to obtain relief from the symptoms
Not recommended
Avoid; strong anticholinergic and sedative effects; may cause orthostatic hypotension (Beers criteria)
Consider alternatives; if must use, initiate with lower initial dose such as 1 tablet (amitriptyline 10 mg/perphenazine 4 mg) three/four times daily
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Frequency Not Defined
Sedation
Fatigue
Constipation
Dry mouth
Lethargy
Weakness
Anticholinergic effects
Blurred vision
Lens opacities
Orthostatic hypotension
Agitation
Anxiety
Headache
Insomnia
Nausea/vomiting
Sweating
Orthostatic hypotension
ECG changes
Tachycardia
Confusion
EPS
Dizziness
Paresthesia
Rash
Increased LFTs
Sexual dysfunction
Tinnitus
Seizure
Agranulocytosis
Thrombocytopenia
Eosinophilia
Leukopenia
SIADH
Antipsychotic side effects
Poikilothermia
Decreased gag reflex
Weight gain
Amenorrhea
Post Marketing Reports
Neuroleptic malignant syndrome
Serotonin syndrome
Warnings
Black Box Warnings
Children & Antidepressants
- In short-term studies, antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults (< 24 years of age) taking antidepressants for major depressive disorders and other psychiatric illnesses. This increase was not seen in patients >24 years of age. A slight decrease in suicidal thinking was seen in adults >65 years. Risks must be weighed in children and young adults against the benefits of taking antidepressants. Patients should be monitored closely for changes in behavior, clinical worsening, and suicidal tendencies. This should be done during the initial 1-2 months of therapy and dosage adjustments. The patient’s family should communicate to the healthcare provider any abrupt changes in behavior. Worsening behavior and suicidal tendencies that are not part of the presenting symptoms may require discontinuation of therapy. This drug is not approved for use in pediatric patients.
Antipsychotics & Dementia
- Patients with dementia-related psychosis that are treated with antipsychotic drugs are at an increased risk of death as shown in short-term controlled trials. The deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. This drug is not approved for the treatment of patients with dementia-related psychosis (See WARNINGS in package insert).
Contraindications
Tricyclic Antidepressant (amitriptyline): hypersensitivity, severe cardiovascular disorder, narrow angle glaucoma, within 14 days of MAOIs (risk of serotonin syndrome), any drugs or conditions that prolong QT interval, acute recovery post-MI
Antipsychotic (perphenazine): hypersensitivity, CNS depression, neuroleptic malignant syndrome, poorly controlled seizure disorder, subcortical braine damage, coma, severe obtundation, high dose CNS depressants, blood dyscrasia, myelosuppression, liver damage
Pregnancy & Lactation
Pregnancy Category: D
Lactation: excreted in breast milk; not recommended
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Amitriptyline: Antidepressant; neurotransmitter (especially norepinephrine and serotonin) reuptake inhibitor; elicits anticholinergic effects
Perphenazine: Antipsychotic agent; elicits moderate anticholinergic effects, weak to moderate sedative effects, strong extrapyramidal effects, and strong antiemetic activity
Pharmacokinetics
Amitriptyline
- Onset of action: 6 weeks
- Half-life: 9-27 hr
- Peak serum time: 4 hr
- Metabolism: Hepatic (CYP2C19, CYP3A4)
- Excretion: Urine (25-50%); bile (small amounts)
Perphenazine
- Half-life: 9-12 hr
- Peak plasma time: 1-3 hr; 2-4 hr (metabolite)
- Metabolism: Hepatic P450 enzyme (CYP2D6)
- Excretion: Urine; feces
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
